Business Wire
27 May 2026, 11:47 UTC · 2h ago
Source · https://www.businesswire.com/news/home/20260526499046/en/American-Cancer-Society-Recommends-Guardant-Health%E2%80%99s-Shield-Blood-Test-in-Updated-Colorectal-Cancer-Screening-Guidelines/
Read source
Search tags
Story key points
2 claims · impact-rated
The American Cancer Society (ACS) has included Guardant Health's Shield blood test in its updated Colorectal Cancer Screening Guidelines. — Inclusion in major clinical guidelines typically drives significant adoption and reimbursement, expanding the addressable market for the product.
+0.80The ACS guidelines specifically recommend Shield for patients who decline or have not completed stool-based or visual examination tests. — Targeting the 'screening gap' population provides a clear clinical pathway for volume growth among non-compliant patients.
+0.50Impact vectors
7 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Ticker attribution
Model heads
The company's Shield blood test was included in the updated American Cancer Society screening guidelines, increasing its clinical adoption.
No ticker relationship head found.
